Medicare AdvantageCoverageLow impact
MA08.023d, Enzyme Replacement for the Treatment of Gaucher's Disease
Independence Blue Cross·Hematology, Endocrinology, Pediatrics +1 more·Medical Policy
Effective date
Jan 2, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.023d for Enzyme Replacement Therapy for Gaucher's Disease has been updated. This affects coverage and billing requirements for enzyme replacement treatments used to treat Gaucher's disease patients under Medicare Advantage plans.
Action Required
By January 2, 2026: Billing team should review the full policy MA08.023d at the IBX medical policy portal to understand any changes to coverage criteria, prior authorization requirements, or documentation needs for enzyme replacement therapy in Gaucher's disease patients. Update billing procedures accordingly for Medicare Advantage claims.